Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06321536 · ClinicalTrials.gov registry record · Phase 2
Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)
A Phase 2 study of Multi-Drug Resistant Organism Colonization, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT06321536 is a Phase 2 study of Multi-Drug Resistant Organism Colonization that is actively recruiting participants, run by Emory University. The registered enrollment target is 60 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT06321536, a Phase 2 study of Multi-Drug Resistant Organism Colonization, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.
Conditions Studied
Interventions
- DRUG Allogeneic Microbiota in Glycerol (9%) (AMG)
Study Locations (4)
Georgia
- A.G Rhodes Wesley Woods - Atlanta
- Emory Long Term Acute Care (LTAC) - Decatur
Illinois
- RML Specialty Hospital - Hinsdale
Pennsylvania
- Penn Medicine Rittenhouse - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06321536
The ClinicalTrials.gov registry entry for NCT06321536 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multi-Drug Resistant Organism Colonization appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic Microbiota in Glycerol (9%) (AMG) is the first listed.
NCT06321536 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Georgia, Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06321536 about?
NCT06321536 is a clinical study titled "Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)". REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT...
What is the current status of trial NCT06321536?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-01-13. Estimated completion is 2026-12.
What conditions does trial NCT06321536 study?
This clinical trial studies the following conditions: Multi-Drug Resistant Organism Colonization.
What interventions are being tested in trial NCT06321536?
The interventions under investigation include: Allogeneic Microbiota in Glycerol (9%) (AMG) (DRUG).
Who is sponsoring clinical trial NCT06321536?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06321536 being conducted?
This trial has 4 study locations across Georgia, Illinois, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.